Successful adult ABO incompatible living donor liver transplantation

Experience with double infusion through the hepatic artery and portal vein

Shogo Kobayashi, Hiroaki Nagano, Shigeru Marubashi, Hiroshi Wada, Yutaka Takeda, Hidetoshi Eguchi, Masahito Tanemura, Koji Umeshita, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

Abstract

Background/Aims: Multiple immunosuppressants, plasma exchanges (PEs), splenectomy, and/ or local infusion therapy (either hepatic artery (HA) or portal vein (PV) infusion) are needed in patients undergoing ABO-incompatible living donor fiver transplantation (LDLT). Local infusion therapy is commonly undertaken using the single route, and double-infusion therapy has scarcely been investigated. Herein, we describe our experience with five ABO-incompatible LDLT patients who received double-infusion therapy via both the HA and PV. Methodology: Five patients (age 43-67 years, with HBV, HBV+HCC, HCV+HCC, PBC, cryptogenic) underwent ABO-incompatible LDLT. Following multiple PEs, LDLT with splenectomy was performed. Triple-immunosuppressant and double-infusion therapy, namely, methylprednisolone and PGE1 via the HA and gabexate mesilate via the PV were employed. Results: All five patients achieved accommodation (22-66 months). One patient experienced transient AMR, and recovered after PE and intraarterial steroid infusion. Four of the five patients experienced PV mural thrombi near the PV catheter and recovered with pharmacological treatment. Conclusion: Thus, double-infusion therapy could also be useful for ABO-incompatible LDLT under control against PV mural thrombi.

Original languageEnglish
Pages (from-to)503-507
Number of pages5
JournalHepato-gastroenterology
Volume58
Issue number106
Publication statusPublished - Mar 1 2011
Externally publishedYes

Fingerprint

Hepatic Veins
Living Donors
Hepatic Artery
Portal Vein
Liver Transplantation
Plasma Exchange
Splenectomy
Immunosuppressive Agents
Therapeutics
Thrombosis
Gabexate
Intra Arterial Infusions
Alprostadil
Methylprednisolone
Catheters
Transplantation
Steroids
Pharmacology

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Successful adult ABO incompatible living donor liver transplantation : Experience with double infusion through the hepatic artery and portal vein. / Kobayashi, Shogo; Nagano, Hiroaki; Marubashi, Shigeru; Wada, Hiroshi; Takeda, Yutaka; Eguchi, Hidetoshi; Tanemura, Masahito; Umeshita, Koji; Doki, Yuichiro; Mori, Masaki.

In: Hepato-gastroenterology, Vol. 58, No. 106, 01.03.2011, p. 503-507.

Research output: Contribution to journalArticle

Kobayashi, S, Nagano, H, Marubashi, S, Wada, H, Takeda, Y, Eguchi, H, Tanemura, M, Umeshita, K, Doki, Y & Mori, M 2011, 'Successful adult ABO incompatible living donor liver transplantation: Experience with double infusion through the hepatic artery and portal vein', Hepato-gastroenterology, vol. 58, no. 106, pp. 503-507.
Kobayashi, Shogo ; Nagano, Hiroaki ; Marubashi, Shigeru ; Wada, Hiroshi ; Takeda, Yutaka ; Eguchi, Hidetoshi ; Tanemura, Masahito ; Umeshita, Koji ; Doki, Yuichiro ; Mori, Masaki. / Successful adult ABO incompatible living donor liver transplantation : Experience with double infusion through the hepatic artery and portal vein. In: Hepato-gastroenterology. 2011 ; Vol. 58, No. 106. pp. 503-507.
@article{9aa08b7eb5dd4be1864fb1383aee1883,
title = "Successful adult ABO incompatible living donor liver transplantation: Experience with double infusion through the hepatic artery and portal vein",
abstract = "Background/Aims: Multiple immunosuppressants, plasma exchanges (PEs), splenectomy, and/ or local infusion therapy (either hepatic artery (HA) or portal vein (PV) infusion) are needed in patients undergoing ABO-incompatible living donor fiver transplantation (LDLT). Local infusion therapy is commonly undertaken using the single route, and double-infusion therapy has scarcely been investigated. Herein, we describe our experience with five ABO-incompatible LDLT patients who received double-infusion therapy via both the HA and PV. Methodology: Five patients (age 43-67 years, with HBV, HBV+HCC, HCV+HCC, PBC, cryptogenic) underwent ABO-incompatible LDLT. Following multiple PEs, LDLT with splenectomy was performed. Triple-immunosuppressant and double-infusion therapy, namely, methylprednisolone and PGE1 via the HA and gabexate mesilate via the PV were employed. Results: All five patients achieved accommodation (22-66 months). One patient experienced transient AMR, and recovered after PE and intraarterial steroid infusion. Four of the five patients experienced PV mural thrombi near the PV catheter and recovered with pharmacological treatment. Conclusion: Thus, double-infusion therapy could also be useful for ABO-incompatible LDLT under control against PV mural thrombi.",
author = "Shogo Kobayashi and Hiroaki Nagano and Shigeru Marubashi and Hiroshi Wada and Yutaka Takeda and Hidetoshi Eguchi and Masahito Tanemura and Koji Umeshita and Yuichiro Doki and Masaki Mori",
year = "2011",
month = "3",
day = "1",
language = "English",
volume = "58",
pages = "503--507",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "106",

}

TY - JOUR

T1 - Successful adult ABO incompatible living donor liver transplantation

T2 - Experience with double infusion through the hepatic artery and portal vein

AU - Kobayashi, Shogo

AU - Nagano, Hiroaki

AU - Marubashi, Shigeru

AU - Wada, Hiroshi

AU - Takeda, Yutaka

AU - Eguchi, Hidetoshi

AU - Tanemura, Masahito

AU - Umeshita, Koji

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background/Aims: Multiple immunosuppressants, plasma exchanges (PEs), splenectomy, and/ or local infusion therapy (either hepatic artery (HA) or portal vein (PV) infusion) are needed in patients undergoing ABO-incompatible living donor fiver transplantation (LDLT). Local infusion therapy is commonly undertaken using the single route, and double-infusion therapy has scarcely been investigated. Herein, we describe our experience with five ABO-incompatible LDLT patients who received double-infusion therapy via both the HA and PV. Methodology: Five patients (age 43-67 years, with HBV, HBV+HCC, HCV+HCC, PBC, cryptogenic) underwent ABO-incompatible LDLT. Following multiple PEs, LDLT with splenectomy was performed. Triple-immunosuppressant and double-infusion therapy, namely, methylprednisolone and PGE1 via the HA and gabexate mesilate via the PV were employed. Results: All five patients achieved accommodation (22-66 months). One patient experienced transient AMR, and recovered after PE and intraarterial steroid infusion. Four of the five patients experienced PV mural thrombi near the PV catheter and recovered with pharmacological treatment. Conclusion: Thus, double-infusion therapy could also be useful for ABO-incompatible LDLT under control against PV mural thrombi.

AB - Background/Aims: Multiple immunosuppressants, plasma exchanges (PEs), splenectomy, and/ or local infusion therapy (either hepatic artery (HA) or portal vein (PV) infusion) are needed in patients undergoing ABO-incompatible living donor fiver transplantation (LDLT). Local infusion therapy is commonly undertaken using the single route, and double-infusion therapy has scarcely been investigated. Herein, we describe our experience with five ABO-incompatible LDLT patients who received double-infusion therapy via both the HA and PV. Methodology: Five patients (age 43-67 years, with HBV, HBV+HCC, HCV+HCC, PBC, cryptogenic) underwent ABO-incompatible LDLT. Following multiple PEs, LDLT with splenectomy was performed. Triple-immunosuppressant and double-infusion therapy, namely, methylprednisolone and PGE1 via the HA and gabexate mesilate via the PV were employed. Results: All five patients achieved accommodation (22-66 months). One patient experienced transient AMR, and recovered after PE and intraarterial steroid infusion. Four of the five patients experienced PV mural thrombi near the PV catheter and recovered with pharmacological treatment. Conclusion: Thus, double-infusion therapy could also be useful for ABO-incompatible LDLT under control against PV mural thrombi.

UR - http://www.scopus.com/inward/record.url?scp=79958160406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958160406&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 503

EP - 507

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 106

ER -